HALIFAX, Nov. 25, 2011 /CNW/ - The Honourable Leona Aglukkaq, Minister
of Health, and Dr. Alain Beaudet, President of the Canadian Institutes
of Health Research (CIHR), today announced that CIHR is ready to accept
research proposals for the Phase I/II clinical trial on Chronic
Cerebrospinal Venous Insufficiency (CCSVI).
"Our Government is committed to helping Canadians with multiple
sclerosis," said Minister Aglukkaq. "This next step will help identify
a proposed clinical trial which can then undergo ethical review. At
every step of this process, patient safety must be first and foremost."
The request for research proposals will be available on CIHR's website
on November 30, 2011. This announcement was made today at the Federal,
Provincial and Territorial Health Ministers Meeting in Halifax, Nova
Scotia. The request for research proposals is a collaborative
initiative between the CIHR and the MS Society of Canada. CIHR will
also continue to work with the provinces and territories as it moves
forward with this initiative.
"Multiple sclerosis (MS) affects thousands of Canadians and their
families. It is imperative given the uncertainties related to CCSVI
and its potential relationship to MS that CIHR support ethical research
based on international standards of excellence to help us better
understand what impact venous angioplasty procedures have on the
clinical outcomes and quality of life of MS patients," said Dr.
Beaudet. "The research evidence to-date is so mixed that the only way
to get to the bottom of this is to conduct a well-designed clinical
trial with appropriate stringent patient safety considerations factored
"We are excited to collaborate with CIHR in bringing the MS community
closer to definitive answers on CCSVI and MS," said Yves Savoie,
President and CEO of the MS Society. "People with MS deserve clarity
about the hope that CCSVI offers as a potential treatment for MS. It is
only through rigorous research that we can get these answers."
On June 29, 2011, the Government of Canada accepted the recommendation
of CIHR's Scientific Expert Working Group on CCSVI and MS to undertake
a small scale Phase I/II clinical trial on CCSVI.
The main objective of the trial is to determine the safety of venous
angioplasty and better evidence on patient outcomes. CIHR will
announce the successful research team in March 2012. The applications
received will undergo rigorous review by an international peer review
committee that will be established over the coming weeks. The selected
team will then need to obtain ethics approval from relevant
institutional research ethics board(s) before conducting the trial.
The Canadian Institutes of Health Research (CIHR) is the Government of
Canada's health research investment agency. CIHR's mission is to create
new scientific knowledge and to enable its translation into improved
health, more effective health services and products, and a strengthened
Canadian health care system. Composed of 13 Institutes, CIHR provides
leadership and support to more than 14,100 health researchers and
trainees across Canada.
Ce document est également disponible en français.
SOURCE Canadian Institutes of Health Research
For further information:
CIHR Media Relations, 613-941-4563, email@example.com